Barbara Dijkman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barbara Dijkman has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Hein J.J. Wellens
Academic Hospital Maastricht
4 shared publicationsE C Cheriex
1 shared publicationH J Wellens
1 shared publication- J L Smeets
From the Department of Cardiology of the University Hospital Maastricht (J.L.R.M.S., L.-M.R., C.T., H.J.J.W.), the Netherlands, and The Bruce Rappaport Faculty of Medicine (S.A.B.-H.), Technion-Israel Institute of Technology, Haifa, Israel
1 shared publication - Luz‐Maria Rodriguez
Department of Cardiology, Academic Hospital Maastricht and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands
1 shared publication
Latest Publications
- 1 September 2001
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 5 (3) , 299-308
Interactions Between Pacing and Arrhythmia Detection Algorithms in the Dual Chamber Implantable Cardioverter Defibrillator
Dual chamber implantable cardioverter defibrillator (ICD) combines the possibility to detect and treat ventricular and atrial arrhythmias with the possibility of modern heart stimulation techniques....
- 1 September 2001
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 5 (3) , 299-308
Interactions Between Pacing and Arrhythmia Detection Algorithms in the Dual Chamber Implantable Cardioverter Defibrillator
Dual chamber implantable cardioverter defibrillator (ICD) combines the possibility to detect and treat ventricular and atrial arrhythmias with the possibility of modern heart stimulation techniques....
- 1 September 2001
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 5 (3) , 309-318
Merits and Limitations of the Mode Switching Rate Stabilization Pacing Algorithms in the Implantable Cardioverter Defibrillator
Background:The 7250 Jewel AF Medtronic model of ICD is the first implantable device in which both therapies for atrial arrhythmias and pacing algorithms for atrial arrhythmia prevention are...
- 1 September 2001
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 5 (3) , 309-318
Merits and Limitations of the Mode Switching Rate Stabilization Pacing Algorithms in the Implantable Cardioverter Defibrillator
Background:The 7250 Jewel AF Medtronic model of ICD is the first implantable device in which both therapies for atrial arrhythmias and pacing algorithms for atrial arrhythmia prevention are...
- 1 December 2000
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 11 (12) , 1309-1319
Importance of the atrial channel for ventricular arrhythmia therapy in the dual chamber implantable cardioverter defibrillator.
- 1 December 2000
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 11 (12) , 1309-1319
Importance of the atrial channel for ventricular arrhythmia therapy in the dual chamber implantable cardioverter defibrillator.
- 1 November 2000
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 11 (11) , 1196-1205
Diagnosis and Therapy of Atrial Tachyarrhythmias in the Dual Chamber Implantable Cardioverter Defibrillator
Atrial Arrhythmias in ICD Patients. Introduction: Devices capable of monitoring and treating atrial taihyarrhythmias provide information about the natural history of the arrbythmias and potentially can influence their natural course by electrical therapy early after onset.Methods and results: Types of atrial arrhythmias and efficacy of device therapies were evaluated in 30 patients implanted with the Medtronic model 7250 Jewel AF implantable cardioverter defibrillator (ICD). All patients had structural heart disease and documented sustained ventricular and atrial arrhythmias (27 with atrial fibrillation [AF]) before implant. Twenty patients were taking amiodarone, and three were taking sotalol. During 20 ± 10 months of follow‐up, 600 atrial arrhythmia recurrences were documented in 50% of patients. AF was diagnosed in 19%. fast polymorphic atrial tacbycardia (AT) in 20%, fast monomorpbic AT in 57%. and slow AT in 4% of episodes. The two adaptive pacing therapies, burst and ramp, together with the 50‐Hz burst, were successful in 57% of delected atrial arrhythmias. Burst and ramp were responsible for 49% and 50‐Hz burst for 51% of successfully treated arrbytbmias; 33% of the episodes terminated spontaneously. No ventricular proarrbythmia was observed due to atrial pacing therapies. In 30% of episodes, dual chamber pacing was required due to post termination bradycardia. Atrial arrhythmia recurrences in patients with dilated cardiomyopathy were not amenable to pacing therapies. Several aspects of atrial arrhythmia diagnosis, therapy, and documentation that are specific for functioning of the Jewel AF arc discussed.Conclusion: Atrial arrhythmias in ICD patients with diseased hearts who are taking Class III antiarrbythmics frequently had longer cycle lengths than AF. Half of these arrhythmias could be terminated with pacing therapies; one third terminated spontaneously.
- 1 November 2000
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 11 (11) , 1196-1205
Diagnosis and Therapy of Atrial Tachyarrhythmias in the Dual Chamber Implantable Cardioverter Defibrillator
Atrial Arrhythmias in ICD Patients. Introduction: Devices capable of monitoring and treating atrial taihyarrhythmias provide information about the natural history of the arrbythmias and potentially can influence their natural course by electrical therapy early after onset.Methods and results: Types of atrial arrhythmias and efficacy of device therapies were evaluated in 30 patients implanted with the Medtronic model 7250 Jewel AF implantable cardioverter defibrillator (ICD). All patients had structural heart disease and documented sustained ventricular and atrial arrhythmias (27 with atrial fibrillation [AF]) before implant. Twenty patients were taking amiodarone, and three were taking sotalol. During 20 ± 10 months of follow‐up, 600 atrial arrhythmia recurrences were documented in 50% of patients. AF was diagnosed in 19%. fast polymorphic atrial tacbycardia (AT) in 20%, fast monomorpbic AT in 57%. and slow AT in 4% of episodes. The two adaptive pacing therapies, burst and ramp, together with the 50‐Hz burst, were successful in 57% of delected atrial arrhythmias. Burst and ramp were responsible for 49% and 50‐Hz burst for 51% of successfully treated arrbytbmias; 33% of the episodes terminated spontaneously. No ventricular proarrbythmia was observed due to atrial pacing therapies. In 30% of episodes, dual chamber pacing was required due to post termination bradycardia. Atrial arrhythmia recurrences in patients with dilated cardiomyopathy were not amenable to pacing therapies. Several aspects of atrial arrhythmia diagnosis, therapy, and documentation that are specific for functioning of the Jewel AF arc discussed.Conclusion: Atrial arrhythmias in ICD patients with diseased hearts who are taking Class III antiarrbythmics frequently had longer cycle lengths than AF. Half of these arrhythmias could be terminated with pacing therapies; one third terminated spontaneously.
- 24 October 1992
- Vol. 136 (43) , 2131-5
[Radiofrequency energy as treatment for arrhythmias in patients with accessory atrioventricular pathways].
Evaluation of the use of radiofrequency energy to interrupt accessory atrioventricular pathways. Prospective study. University Hospital Maastricht. The outcome is presented of radiofrequency catheter ablation of accessory atrioventricular pathways in our first 50 consecutive patients, with a total of 54 accessory pathways. All but one patient suffered from symptomatic tachycardias. A catheter electrode was positioned next to the accessory pathway and 30 second pulses of 40 W radiofrequency energy were used to interrupt the connection. Complete block in conduction was accomplished in 44/54 (81%) of accessory pathways. No complications occurred. Success rate, procedure time and radiation dose were found to be related to the location of the accessory connection. The highest success rate was found in left free wall pathways (24/26; 92%), the lowest in right lateral pathways which seldom occur (1/4; 25%). The total procedure took 1-6 hours. The maximal duration of radiographic imaging was 2.5 hours. Although insufficient information on long-term efficacy is available, current results support the use of radiofrequency ablation of accessory pathways in institutions with expertise in the invasive management of cardiac arrhythmias. Technical improvements leading to reduction in procedure time and radiation dose will facilitate acceptance of this technique by patient and operator.
- 24 October 1992
- Vol. 136 (43) , 2131-5
[Radiofrequency energy as treatment for arrhythmias in patients with accessory atrioventricular pathways].
Evaluation of the use of radiofrequency energy to interrupt accessory atrioventricular pathways. Prospective study. University Hospital Maastricht. The outcome is presented of radiofrequency catheter ablation of accessory atrioventricular pathways in our first 50 consecutive patients, with a total of 54 accessory pathways. All but one patient suffered from symptomatic tachycardias. A catheter electrode was positioned next to the accessory pathway and 30 second pulses of 40 W radiofrequency energy were used to interrupt the connection. Complete block in conduction was accomplished in 44/54 (81%) of accessory pathways. No complications occurred. Success rate, procedure time and radiation dose were found to be related to the location of the accessory connection. The highest success rate was found in left free wall pathways (24/26; 92%), the lowest in right lateral pathways which seldom occur (1/4; 25%). The total procedure took 1-6 hours. The maximal duration of radiographic imaging was 2.5 hours. Although insufficient information on long-term efficacy is available, current results support the use of radiofrequency ablation of accessory pathways in institutions with expertise in the invasive management of cardiac arrhythmias. Technical improvements leading to reduction in procedure time and radiation dose will facilitate acceptance of this technique by patient and operator.